Management of Metabolic Effects Associated With Anticancer Agents Targeting the PI3K-Akt-mTOR PathwayNaifa L. Busaidy, Lillian L. Siu, Joanna M. Brell et al.|Journal of Clinical Oncology|2012Cited by 231
Effect of Capivasertib in Patients With an <i>AKT1 E17K</i>-Mutated TumorKevin Kalinsky, Keith T. Flaherty, Fangxin Hong et al.|JAMA Oncology|2020Cited by 106
A Phase II Trial of Neoadjuvant MK-2206, an AKT Inhibitor, with Anastrozole in Clinical Stage II or III <i>PIK3CA</i> -Mutant ER-Positive and HER2-Negative Breast CancerX. Cynthia, Matthew J. Ellis, Vera J. Suman et al.|Clinical Cancer Research|2017Cited by 74